ArticleBiomedical engineering online2024
Optimizing stent retrievers for mechanical enhancement and in vitro testing in acute ischemic stroke models.
Article in Biomedical engineering online, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stent retrievers for acute ischemic stroke: technological advances, clinical applications, and future perspectives.Journal of neurology · 2026Review
- Innovation and development of stent retrievers in acute ischemic stroke.Frontiers of medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAcute ischemic stroke (AIS) remains a major cause of morbidity and mortality worldwide. Mechanical thrombectomy, especially with stent retrievers, offers a promising treatment, particularly for patients ineligible for intravenous tissue plasminogen activator (IV tPA) therapy. This study aimed to develop and evaluate novel stent retriever designs to enhance mechanical properties and vessel compatibility.
resultsWe evaluated four stent designs using finite-element analysis (FEA) to assess their mechanical properties. Based on these evaluations, Stent D emerged as the optimal design due to its superior elasticity and adaptability. Comparative testing of Stent D against commercial stents, Solitaire FR and Trevo XP ProVue, revealed the following metrics: radial forces of 3.77 ± 0.01 N for Solitaire FR, 3.92 ± 0.08 N for Trevo XP ProVue, and 4.10 ± 0.07 N for Stent D; flexibility measurements of 0.38 ± 0.11 N for Solitaire FR, 0.91 ± 0.11 N for Trevo XP ProVue, and 0.59 ± 0.05 N for Stent D; deployment forces of 0.37 ± 0.02 N for Solitaire FR, 0.42 ± 0.04 N for Trevo XP ProVue, and 0.32 ± 0.02 N for Stent D; and recapture forces of 0.38 ± 0.01 N for Solitaire FR, 0.45 ± 0.02 N for Trevo XP ProVue, and 0.35 ± 0.01 N for Stent D. Thrombus retrieval rates were 96.16% for Solitaire FR and 95.51% for Stent D.
conclusionsThese findings demonstrate that Stent D performs comparably to commercial stents, highlighting its effective performance in AIS treatment. Stent D shows promise as a candidate for further clinical evaluation due to its superior mechanical properties and effective thrombus retrieval capabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.